Table 2.
Comparison of Molecular Features of DLBCL Patients with High or Low p-AKT Expression
| Variable | DLBCL |
GCB-DLBCL |
ABC-DLBCL |
||||||
|---|---|---|---|---|---|---|---|---|---|
| p-AKThigh | p-AKTlow | P | p-AKThigh | p-AKTlow | P | p-AKThigh | p-AKTlow | P | |
| IL-6 expression | |||||||||
| Positive | 24 (20.7) | 40 (10.9) | 0.011 | 8 (15.1) | 21 (11.2) | 0.48 | 16 (25.4) | 19 (10.9) | 0.011 |
| PI3K expression | |||||||||
| ≥70% | 40 (36.4) | 98 (27.8) | 0.095 | 16 (31.4) | 44 (24.3) | 0.22 | 24 (40.7) | 52 (30.8) | 0.2 |
| p-STAT3 expression | |||||||||
| >40% | 25 (25.8) | 45 (13.7) | 0.008 | 7 (14.6) | 17 (10.2) | 0.44 | 18 (36.7) | 28 (17.4) | 0.006 |
| Myc expression | |||||||||
| ≥70% | 59 (46.8) | 111 (28.9) | <0.0001 | 31 (51.7) | 41 (20.9) | <0.0001 | 28 (42.4) | 69 (37.5) | 0.56 |
| Bcl-2 expression | |||||||||
| ≥70% | 82 (65.6) | 160 (41.6) | <0.0001 | 35 (59.3) | 66 (33.2) | <0.0001 | 47 (71.2) | 94 (51.6) | 0.006 |
| Mychigh/Bcl-2high | |||||||||
| + | 36 (28.8) | 58 (15.1) | 0.0006 | 15 (25.4) | 17 (8.7) | 0.0007 | 21 (31.8) | 41 (22.3) | 0.12 |
| MYC translocation | |||||||||
| + | 13 (15.7) | 25 (10.1) | 0.17 | 10 (27.8) | 15 (12.4) | 0.037 | 3 (6.4) | 10 (7.9) | 1.0 |
| BCL2 translocation | |||||||||
| Positive | 23 (22.3) | 50 (15.9) | 0.14 | 20 (41.7) | 44 (28.2) | 0.11 | 3 (5.5) | 6 (3.8) | 0.7 |
| TP53 mutation | |||||||||
| Positive | 15 (13.8) | 87 (24.6) | 0.017 | 10 (19.2) | 53 (29.0) | 0.21 | 5 (8.8) | 34 (20.6) | 0.045 |
| WT-p53 expression | |||||||||
| ≥20% | 32 (34.4) | 57 (22.5) | 0.027 | 14 (34.1) | 29 (23.4) | 0.22 | 18 (34.6) | 28 (21.7) | 0.089 |
| Bcl-6 expression | |||||||||
| >30% | 103 (83.1) | 284 (74.3) | 0.05 | 54 (91.5) | 170 (85.0) | 0.28 | 49 (75.4) | 114 (62.6) | 0.069 |
| CD10 expression | |||||||||
| ≥30% | 59 (46.5) | 146 (37.9) | 0.095 | 51 (83.6) | 132 (65.7) | 0.007 | 8 (12.1) | 14 (7.6) | 0.31 |
| FOXP1 expression | |||||||||
| ≥60% | 93 (73.8) | 208 (54.3) | <0.0001 | 37 (61.7) | 58 (29.1) | <0.0001 | 56 (84.8) | 150 (81.5) | 0.16 |
| BLIMP-1 expression | |||||||||
| ≥10% | 42 (35.0) | 83 (22.1) | 0.008 | 10 (17.5) | 25 (12.9) | 0.39 | 32 (50.8) | 57 (31.8) | 0.01 |
| NF-κB1/p50 nuclear expression | |||||||||
| Positive | 40 (38.1) | 199 (56.7) | 0.001 | 13 (25.0) | 85 (47.5) | 0.004 | 27 (50.9) | 113 (66.1) | 0.053 |
| NF-κB2/p52 nuclear expression | |||||||||
| Positive | 16 (14.0) | 123 (34.4) | <0.0001 | 7 (13.2) | 64 (35.2) | 0.002 | 9 (14.8) | 58 (33.3) | 0.005 |
| c-Rel nuclear expression | |||||||||
| Positive | 14 (13.0) | 122 (35.5) | <0.0001 | 5 (9.6) | 61 (35.3) | <0.0001 | 9 (16.1) | 60 (35.3) | 0.007 |
Data are expressed as n (%) unless otherwise indicated. Percentages were calculated as positive cases/total cases with results available. Bold indicates significant values.
ABC, activated B-cell–like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell–like; p-AKThigh, high levels (≥70%) of phospho-AKT expression; p-AKTlow, low levels (<70%) of phospho-AKT expression; PI3K, phosphatidylinositol 3-kinase; WT, wild-type.